New drug combo aims to spare bladders in cancer patients

NCT ID NCT07475806

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 7 times

Summary

This phase 2 trial tests whether a combination of enfortumab vedotin and pembrolizumab can help people with muscle-invasive bladder cancer avoid bladder removal. About 240 adults who are candidates for surgery will receive the drugs intravenously. The main goals are to see how many achieve a complete response and keep their bladder for at least 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin and pembrolizumab
What this could lead to: If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, preserving quality of life.
What could go wrong: This is a mid-stage trial with no control group, so results are uncertain. The treatment may not work for everyone, and side effects like nerve damage or uncontrolled diabetes could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE-INVASIVE BLADDER CANCER

Contacts and locations

Locations

Accellacare of Duly
RECRUITING

Lisle, Illinois, 60532, United States
Arkansas Urology Associates
RECRUITING

Little Rock, Arkansas, 72211, United States
Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Centers for Advanced Urology, LLP
RECRUITING

Bala-Cynwyd, Pennsylvania, 19004, United States
Institute of Science Tokyo Hospital
RECRUITING

Bunkyo-ku, Tokyo, Japan
KR82008
RECRUITING

Seoul, South Korea
Kyoto University Hospital
RECRUITING

Kyoto, Japan
NYU Langone Urology Associates
RECRUITING

New York, New York, 10017, United States
Osaka Metropolitan University Hospital
RECRUITING

Osaka, Japan
Profound Research LLC at Michigan Hematology and Oncology Consultants
RECRUITING

Royal Oak, Michigan, 48073, United States
Sidney Kimmel Comprehensive Cancer - Asplundh Cancer Pavilion
RECRUITING

Willow Grove, Pennsylvania, 19090, United States
Sidney Kimmel Comprehensive Cancer Center (SKCC) Washington Township
RECRUITING

Washington Township, New Jersey, 08080, United States
Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cherry Hill
RECRUITING

Cherry Hill, New Jersey, 08002, United States
Site KR82001
RECRUITING

Seoul, South Korea
Site KR82002
RECRUITING

Seongnam-si, Gyeonggi-do, South Korea
Site KR82003
RECRUITING

Seoul, South Korea
The Cancer Institute Hospital-Japanese Foundation for Cancer
RECRUITING

Koto-ku, Tokyo, Japan
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Tokyo Metropolitan Hospital Organization-Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
RECRUITING

Bunkyo-ku, Tokyo, Japan
University of Illinois College of Medicine - UIC Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States
University of Tsukuba Hospital
RECRUITING

Tsukuba, Ibaraki, Japan
Urology San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Yamaguchi University Hospital - Center For Clinical Research
RECRUITING

Ube, Yamaguchi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.